Agenus announces preclinical data on bms-986442 (agen1777) at aacr 2024

Lexington, mass.--(business wire)--agenus inc. (“agenus”) (nasdaq: agen), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from bms-986442 (agen1777) will be presented in an oral presentation at the upcoming aacr meeting, to be held april 5 – 10, 2024 in san diego, ca. in non-clinical assays, bms-986442 demonstrated superior immune activation both as monotherapy and in combination with pd-(l)1 blockade co.
AGEN Ratings Summary
AGEN Quant Ranking